เปรียบเทียบวิธี

	การออกแบบการศึกษาความแม่นยำในการวินิจฉัย	การประเมินการทดสอบคัดกรอง
สาขาวิชา	การวิจัยทางคลินิก	ระบาดวิทยา
ตระกูล	Process / pipeline	Process / pipeline
ปีกำเนิด	2003-2015	1968 (Wilson-Jungner principles); statistical framework developed 1970s–2000s
ผู้ริเริ่ม	Bossuyt, Reitsma, and STARD group (2003); clinical epidemiology pioneers	Wilson & Jungner (WHO criteria, 1968); foundational work by Pepe, Altman, and others in statistical test evaluation
ประเภท	Research Design	Observational diagnostic / epidemiological evaluation design
แหล่งต้นตำรับ	Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., ... & de Vet, H. C. (2003). Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Annals of Internal Medicine, 138(1), 40–44.	Wilson, J. M. G., & Jungner, G. (1968). Principles and Practice of Screening for Disease. World Health Organization. Public Health Papers No. 34.
ชื่อเรียกอื่น	diagnostic accuracy study, test accuracy, STARD, diagnostic evaluation	screening study, screening performance evaluation, screening accuracy assessment, STE
ที่เกี่ยวข้อง	2	6
สรุป	A diagnostic accuracy study evaluates how well a new diagnostic test (or biomarker, imaging modality, clinical assessment) detects the presence or absence of disease compared to a reference standard (gold standard). Standardized since 2003 by the STARD (Standards for Reporting of Diagnostic Accuracy Studies) initiative, diagnostic accuracy studies are fundamental to clinical medicine, determining whether and how new tests can improve patient diagnosis and treatment.	Screening test evaluation is a systematic epidemiological approach for assessing whether a test or program can accurately and cost-effectively identify individuals with a condition before symptoms appear. It quantifies diagnostic performance metrics — sensitivity, specificity, predictive values, and the ROC curve — and evaluates whether a screening program meets established public health criteria for adoption and harm-benefit balance.